Navigation Links
ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
Date:6/24/2011

PRAGUE, Czech Republic, June 24, 2011 /PRNewswire/ --


 

The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course of rituximab for remission induction and maintenance over a period of 18 months proved to be as effective as standard therapy.

Hemodiafiltration reduces mortality only if high substitution volumes are used

The prospective, randomised CONTRAST study (abstract no. 2507) aimed to evaluate whether treatment with HDF reduces overall mortality compared with low-flux HD. In the outcome there was no difference between the two groups regarding the incidence of overall mortality, but a subgroup analysis indicated that patients who had reached a substitution volume of over 20 litres/treatment had a significantly lower mortality risk than patients with lower substitution volumes (HR 0.66; p = 0.03).

The prospective, randomised, controlled TURKISH HDF study (abstract no. 2506) compared HDF with large pore hemodialysis (HD) in terms of morbidity and mortality. The difference in terms of mortality was not significant (p = 0.28), but a subgroup analysis showed that HDF patients with a high substitution volume of > 17.4 litres/treatment had a significantly better cardiovascular and overall survival rate.

Bardoxolone improves renal function in type II diabetics with nephropathy

A double-blind, placebo-controlled multi-centre phase II study (abstract no. 2501) randomized 227 type II diabetics with moderate to severe CKD (eGFR 20-45 ml/min/1.73m?) in four different groups.

Significant improvements in GFR were reported in all the bardoxolone groups compared to the placebo group (p<0.001). Other renal function parameters (creatinine and urea) were also better in the Bardoxolone group.

For further information, please see:

http://www.eraedta2011.org/press.html

Bettina Albers

3643776423

albers@albersconcept.de



'/>"/>
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDTA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
2. Dyadic to Present at the World Congress on Industrial Biotechnology & Bioprocessing
3. ACT Interim Chairman and CEO Gary Rabin to Present at World Stem Cells & Regenerative Medicine Congress in London
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics
6. NOVAVAX to Present at BIT Life Sciences 3rd World Congress of Vaccine
7. Former U.S. Congressman Curt Weldon to Represent Regenicin at 2011 Future of Financial Markets Conference in Mumbai
8. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
9. Brazilian Sugarcane Industry Association Says Lame-Duck Congress Goes from Bad to Worse on Ethanol Policy
10. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
11. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec 2, 2016 Research ... report "Nanobiotechnology Applications, Markets and Companies" to their ... , , ... nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology ... from formulations for optimal delivery to diagnostic applications in clinical ...
(Date:12/2/2016)... ... ... The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° ... 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr ... approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific ...
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:11/30/2016)... The global Pyrogen Testing Market ... dominant share in the overall market. The leading players, ... Merck KGaA, held a lion,s share of 51% in ... that these companies are expected to retain their leadership ... do not require rabbit pyrogen testing along with strategic ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):